共 43 条
[1]
De Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Et al., Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts, Neurology, 54, 11 SUPPL. 5, pp. 21-23, (2000)
[2]
Canadian guidelines on Parkinson's disease, Can J Neurol Sci, 39, SUPPL. 4, pp. 1-30, (2012)
[3]
Olanow C.W., Stern M.B., Sethi K., The scientific and clinical basis for the treatment of Parkinson disease (2009), Neurology, 72, 21 SUPPL. 4, (2009)
[4]
Lewitt P.A., Levodopa for the treatment of Parkinson's disease, N Engl J Med, 359, 23, pp. 2468-2476, (2008)
[5]
Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M., Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 68, 5, pp. 384-386, (2007)
[6]
Pinder R.M., Drugs for Parkinson's disease: Levodopa is still the gold standard, Neuropsychiatric Disease and Treatment, 4, 1 A, (2008)
[7]
Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa, New England Journal of Medicine, 342, 20, pp. 1484-1491, (2000)
[8]
(2011)
[9]
Miyasaki J.M., Martin W., Suchowersky O., Weiner W., Lang A., Initiation of Treatment of Parkinson's Disease (Internet), (2006)
[10]
Schapira A.H.V., Treatment options in the modern management of Parkinson disease, Archives of Neurology, 64, 8, pp. 1083-1088, (2007)